Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs051220109
JPRN-jRCTs051220109
Recruiting
未知

Evaluation of treatment response for immune checkpoint inhibitors in non-small cell lung cancer patients using [18F]F-AraG PET/CT

akamoto Yuji0 sites60 target enrollmentOctober 26, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
akamoto Yuji
Enrollment
60
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 26, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
akamoto Yuji

Eligibility Criteria

Inclusion Criteria

  • •1\) Confirmed non\-small cell lung cancer by pathology.
  • •2\) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2\.
  • •3\) Patients without history of immune checkpoint inhibitors approved in Japan, but clinically applicable and planned to be prescribed.
  • •4\) Patients who performed FDG\-PET/CT

Exclusion Criteria

  • •1\) Pregnant, possibly pregnant, or breastfeeding women.
  • •2\) Very poor physical condition.
  • •3\) Outstandingly difficult in communication.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy Subject
JPRN-UMIN000045492Shionogi & Co., Ltd.143
Recruiting
Not Applicable
Study protocol for the HARMONY study
KCT0005173Korea Institute of Oriental Medicine200
Completed
Not Applicable
Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancerlung cancer
JPRN-UMIN000033594Japanese Red Cross Medical Center37
Completed
Not Applicable
Prospective study on evaluation of immunological response after SARS-CoV-2 vaccinatioCOVID-19
JPRN-UMIN000045097Shionogi & Co., Ltd.205
Active, not recruiting
Phase 1
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56